Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ROCHESTER, N.Y., Oct. 12, 2016 -- Transcat, Inc. (NASDAQ:TRNS), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it will release its second quarter fiscal year 2017 results after the close of financial markets on Tuesday, October 25, 2016.
The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its corporate strategy and outlook. A question-and-answer session will follow.
Second Quarter Fiscal Year 2017 Conference Call
Wednesday, October 26, 2016
11:00 a.m. Eastern Time
Phone: (201) 689-8471
Internet Webcast: www.transcat.com/investor-relations
A telephonic replay will be available from 2:00 p.m. ET on the day of the teleconference until Wednesday, November 2, 2016. To listen to the archived call, dial (858) 384-5517 and enter conference ID number 13645487, or access the webcast replay at www.transcat.com/investor-relations, where a transcript will be posted once available.
ABOUT TRANSCAT
Transcat, Inc. is a leading provider of accredited calibration, repair, inspection and laboratory instrument services. The Company is focused on providing best-in-class services and products to highly regulated industries, including life science, aerospace and defense, pharmaceutical, medical device manufacturing and biotechnology. Transcat provides permanent and periodic on-site services, mobile calibration services and in-house services through 20 Calibration Service Centers strategically located across the United States, Puerto Rico and Canada. The breadth and depth of measurement parameters addressed by Transcat’s ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry.
Transcat also operates as a leading value-added distributor that markets, sells and rents national and proprietary brand instruments to customers globally. Its e-commerce focused website and product catalog offer access to more than 100,000 test, measurement and control instruments, including products from approximately 540 leading manufacturers.
Transcat’s growth strategy is to leverage its service capabilities, strong brand and leading distribution platform to drive organic sales growth and to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model.
More information about Transcat can be found on its website at: Transcat.com.
For more information contact: Michael J. Tschiderer, Chief Financial Officer Phone: (585) 352-7777 Email: [email protected] Deborah K. Pawlowski, Investor Relations Phone: (716) 843-3908 Email: [email protected]
